Press release
Anaplastic Astrocytoma Market Outlook, Current And Future Industry Landscape Analysis 2033
The new report published by The Business Research Company, titled Anaplastic Astrocytoma Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.As per the report, the anaplastic astrocytoma market size has grown strongly in recent years. It will grow from $6.27 billion in 2023 to $6.62 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The anaplastic astrocytoma market size is expected to see steady growth in the next few years. It will grow to $7.99 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%.
Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12874&type=smp
Rising Incidence Of Brain Tumors Fuels Growth In The Anaplastic Astrocytoma Market
The growing incidence of primary malignant and non-malignant brain tumors is expected to propel the growth of the anaplastic astrocytoma market. Brain tumors are growths in the brain that can be classified as either cancerous (malignant) and invasive or non-cancerous (benign) and non-invasive, with varying degrees of aggressiveness and potential to spread. The anaplastic astrocytoma treatment removes the tumor and surrounding affected tissue while preserving brain function. For instance, in March 2023, according to the American Society of Clinical Oncology (ASCO), a US-based non-profit organization, approximately 24,810 adults in the United States are expected to receive a diagnosis of primary cancerous tumors originating in the brain and spinal cord, with 14,280 cases among men and 10,530 among women. Therefore, the growing incidence of primary malignant and non-malignant brain tumors will drive the growth of the anaplastic astrocytoma market going forward.
Innovative Approaches In The Anaplastic Astrocytoma Market Boost Enhanced Patient Outcome
Major companies operating in the anaplastic astrocytoma market are innovating novel treatment options to enhance efficacy, minimize side effects and improve patient outcomes. For instance, in June 2022, the U.S. Food and Drug Administration, a US-based federal agency, granted accelerated approval for a novel treatment combination comprising the oral drugs dabrafenib (Tafinlar) and trametinib (Mekinist) for advanced brain tumors with the BRAF V600E mutation. This approval applies to adult and pediatric patients with high- and low-grade gliomas that have progressed after prior treatment. The BRAF V600E mutation is prevalent in various glioma types, including low-grade gliomas, pleomorphic xanthoastrocytomas (PXA), gangliogliomas and pilocytic astrocytoma. The approval was based on clinical trials for the Tafinlar-Mekinist combination therapy that led to tumor shrinkage benefits for both adult and pediatric glioma patients, with a 33% response rate observed in high-grade glioma patients, a 50% response rate in low-grade glioma patients and a 25% response rate in pediatric glioma patients.
The anaplastic astrocytoma market covered in this report is segmented -
1) By Disease Type: Grade I; Grade II; Grade III; Grade IV
2) By Treatment Type: Surgery; Chemotherapy; Radiation
3) By Treatment Phase: Pre-Registration Phase; Clinical Trial Phase
4) By End-User: Hospitals And Clinics; Retail Pharmacy; Online Pharmacy
Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12874&type=discount
Major players in the anaplastic astrocytoma market are Pfizer Inc., Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Eisai Co. Ltd., Boehringer Ingelheim International GmbH, Perrigo Company PLC, Ipsen SA, Genentech Inc., Cipla Limited, Novocure Ltd., Celon Laboratories Limited, Avid Bioservices Inc., EirGen Pharma Ltd., Monteris Medical Corporation, GLS Pharma Pvt. Ltd., Tocagen Inc., Pharma's Almanac, Inovio Pharmaceuticals Inc., Isarna Therapeutics GmbH, Actiza Pharmaceutical Private Limited, Celldex Therapeutics Inc.
Contents of the report:
1. Executive Summary
2. Anaplastic Astrocytoma Market Report Structure
3. Anaplastic Astrocytoma Market Trends And Strategies
4. Anaplastic Astrocytoma Market - Macro Economic Scenario
5. Anaplastic Astrocytoma Market Size And Growth
…..
27. Anaplastic Astrocytoma Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/anaplastic-astrocytoma-global-market-report
Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anaplastic Astrocytoma Market Outlook, Current And Future Industry Landscape Analysis 2033 here
News-ID: 3618720 • Views: …
More Releases from The Business research company
Dental Anesthesia Market Report Evaluates Growth Drivers, Challenges And Market …
The dental anesthesia sector is poised for significant growth as advancements in technology and evolving patient needs drive demand. With innovations improving safety and effectiveness, the market is expected to witness notable expansion over the coming years. Let's explore the current market size, key players, emerging trends, and segmentation that define the dental anesthesia industry today.
Projected Market Size and Growth Outlook for the Dental Anesthesia Industry
The dental anesthesia…
Demulcent Eye Drops Market Report Provides Insights Into Market Evolution And Gr …
The demulcent eye drops market is positioned for notable expansion in the coming years, driven by rising awareness about eye health and advances in product formulations. As consumers increasingly seek effective solutions for dry eye and related conditions, this market is expected to experience robust growth along several key dimensions.
Projected Market Value and Growth Outlook for Demulcent Eye Drops
By 2030, the demulcent eye drops market size is forecasted…
Deep Learning In Drug Discovery And Diagnostics Market Research Explores Growth …
The deep learning sector within drug discovery and diagnostics is rapidly evolving, driven by innovations that promise to transform healthcare. As artificial intelligence technologies become increasingly integrated into life sciences, the market is set to experience remarkable growth. Below, we explore the current market valuation, key players, emerging trends, and detailed segmentation to provide a comprehensive overview of this dynamic field.
Market Valuation Outlook for Deep Learning in Drug Discovery and…
Decentralized Trial Wearable Market Analysis Highlights Growth To $6.18 Billion …
The decentralized trial wearable industry is set to undergo remarkable expansion over the coming years, driven by technological advancements and evolving clinical research needs. This sector is increasingly attracting attention due to its potential to transform how clinical trials are conducted by enhancing remote patient monitoring and data accuracy. Let's explore the market's current outlook, key players, emerging trends, and the segments shaping its future trajectory.
Forecasted Market Value and Growth…
More Releases for Anaplastic
Emerging Sub-Segments Transforming the Anaplastic Astrocytoma Market Landscape
The anaplastic astrocytoma market is set to experience significant growth as advancements in neuro-oncology and precision medicine continue to evolve. With increasing research investments and improved treatment options, this sector is gaining momentum, offering promising opportunities for innovation and patient care enhancements in the coming years.
Projected Growth and Market Size of the Anaplastic Astrocytoma Market by 2030
The anaplastic astrocytoma market is forecasted to expand markedly, reaching a valuation of…
Anaplastic Astrocytoma Market Outlook, Epidemiology, Landscape and Growth Trajec …
Anaplastic astrocytoma (AA) is a rare, malignant brain tumor classified as World Health Organization (WHO) Grade III glioma, characterized by its aggressive nature and poor prognosis. While not as common as glioblastoma, anaplastic astrocytoma represents a significant challenge due to its high recurrence rates, limited treatment options, and resistance to conventional therapies.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70897
Over the past decade, the treatment landscape has slowly evolved…
Anaplastic Astrocytoma Market Development, Trends, Segmentations Analysis
Anaplastic astrocytoma is a very rare type of malignant brain tumor affecting human at all ages. As this tumor develops from astrocytes, the star-shaped brain cells it is termed as astrocytoma. The astrocytes along with other cells protect nerve cells in the brain and spinal cord by surrounding them. All these protective cells are collectively termed as glial cells. World Health Organization (WHO) graded these tumors on a scale from…
Anaplastic Astrocytoma - Pipeline Review, H2 2017 - Pharmaceutical Report
Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among…
Anaplastic Oligoastrocytoma Market Snapshot by 2024 – Persistence Market Resea …
Oligoastrocytomas is a part of a group of brain tumor called “gliomas”. Glioma tumor is originated in the brain or spine. Oligoastrocytomas contains both astrocytoma cells and oligodendroglioma. About 2.3% of the brain tumors reported are diagnosed as oligoastrocytomas. Oligoastrocytomas is divided into two parts, low grade and anaplastic. According to the WHO grading system, anaplastic oligoastrocytomas are usually identify as grade 1 and grade 2 but sometimes they appear…
Latest Report Details Of Global Anaplastic Thyroid Cancer Market
Marketresearchreports.biz has added a new research report on the "Anaplastic Thyroid Cancer-Pipeline Insights, 2017" to its collection.
DelveInsights, Anaplastic Thyroid Cancer- Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Anaplastic Thyroid Cancer. The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical…
